CASE REPORT

Arterio-venous fistula—expanding role for venous access in mastocytosis patients

Han Nien Beh and Kishore Sieunarine*

Department of Vascular Surgery, Joondalup Health Campus, Joondalup, WA, Australia

*Correspondence address. Department of Vascular Surgery, Joondalup Health Campus, Crn of Shenton Ave and Grand Blvd, Joondalup 6027, WA, Australia. Tel: +61 8 9400 9400; E-mail: ksieunar@bigpond.net.au

Abstract

Long-term central venous access is increasingly common as there are growing number of patients suffering from conditions that require repeated infusions for various indications. However, central venous access has its downside where there is a risk of infection and thrombosis (F Pinelli, E Cecero, D Del’Innocenti, V Selmi, R Giua, G Villa et al., ‘Infection of totally implantable venous access devices: a review of literature,’ J Vasc Access 2018;19: 230–42.). Arterio-venous (AV) fistula is traditionally used for haemodialysis, however in patients requiring repeated access or long-term central venous access it can be considered as an unconventional solution.

We report a case where 61-year-old male who has a history of systemic mastocytosis. He presents frequently to the Emergency Department with anaphylactic reaction requiring intravenous adrenaline, antihistamine and steroids. He had multiple issues with central lines as well as ports including line sepsis and thrombosis. On further discussion, an arterio-venous fistula was considered and surgically created to allow the AV fistula to be cannulated directly or under ultrasound guidance with its advantage it can be accessed rapidly in emergency setting.

INTRODUCTION

Mastocytosis is one of the eight subcategories of myeloproliferative neoplasms. It results from a clonal, neoplastic proliferation of morphologically and immunophenotypically abnormal mast cell that accumulate in one or more organ systems [1]. Clinical presentation of mastocytosis is heterogenous, ranging from skin-limited disease to a more aggressive variant with extracutaneous involvement (systemic mastocytosis) that may be associated with multiorgan dysfunction/failure and shortened survival [1]. Systemic mastocytosis can often present with pruritus/flushing, abdominal pain, cramps, diarrhoea, nausea and vomiting [2]. Patients often present following systemic mast cell degranulation resulting in anaphylaxis.

CASE STUDY

A 63-year-old man with long history of systemic mastocytosis. Due to his condition, having central venous access is crucial for rapid administration of adrenaline and antihistamines during anaphylaxis. The condition was diagnosed at the age 47 following an anaphylactic reaction that resulted in 3 months stay in intensive care unit (ICU). He initially had insertion of infusion port into his right subclavian vein for central venous access. Unfortunately, the port became colonized with Staphylococcus aureus within 18 months which he was admitted for bacteraemia and septic shock. He spent another 3 weeks in ICU battling severe line sepsis which resulted in multi-organ failure. He was discharged home after 4 weeks of intravenous antibio-
tics and managed to salvage the infusaport. The infusaport was later colonized with *Escherichia coli*, the decision was made to remove the infected port. A peripheral inserted central catheter (PICC) was inserted as a replacement for his central venous access. 3 months later, a replacement infusaport was inserted. This infusaport remained thrombus and infection free for 5 years until it became infected with *Staphylococcus aureus*. After consulting with vascular surgeon, the decision to surgically created arteriovenous fistula (AVF) was made. The principle was to remove any potential form of infection while maintaining vascular access and central venous patency.

The patient began work up for AVF including ultrasound venous mapping of the upper arms, and education in managing and care for AVF. Two weeks later, he underwent left brachio/radiocephalic AVF formation under IV sedation with local anaesthesia. The patient was followed up in clinic, AVF had matured by 8 weeks and PICC line was subsequently removed. For 12 months the patient was cannulated on weekly basis for administration of antihistamines, adrenaline, corticosteroids with no complications reported. He was later commenced on Midostaurin which reduced his incidents of anaphylactic reactions.

**DISCUSSION**

Anaphylactic reaction from mastocytosis requires urgent access to patient’s central venous system from adrenaline infusion. In emergency setting where patient is having an anaphylaxis, rapid access is essential and potentially lifesaving.

Central venous catheters with or without ports are traditionally inserted for long-term intravenous access but are prone to several complications. These include pneumothorax (1.3–1.5%), sepsis (4–8.6%) and thrombosis (1.2%) [3]. Totally implantable venous access devices have infection rates ranging from 0.018/1000 catheter days to 0.35/1000 catheter days in adults [4–8]. Permanent catheter showed higher infection rates, catheter dysfunction and thrombosis compare to AVF [9]. Estimated cost of implantable device is ranging from Australian $2186–$2274, where AVF cost Australian $1636. This makes AVF more cost effective.

Sure, traditionally AVF is a preferred haemodialysis access where the fistula is accessed usually three times a week and as a result this access is an option that needs to be considered for any patients required long-term central venous access for repetitive administration of drugs e.g. antibiotics, etc.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**

1. Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. *Am J Hematol* 2016;91:1146–59.
2. Scherber RM, Borate U. How we diagnose and treat systemic mastocytosis in adults. *Br J Haematol* 2018;180:11–23.
3. Ruesch S, Walder B, Tramer MR. Complications of central venous catheters: internal jugular versus subclavian access—a systematic review. *Critical Care Med* 2002;30:454–60.
4. Shim J, Seo TS, Song MG, Cha IH, Kim JS, Choi CW, et al. Incidence and risk factors of infectious complications related to implantable venous-access ports. *Korean J Radiol* 2014;15:494–500.
5. Buscgh JD, Hermann J, Heller F, Derlin T, Koops A, Adam G, et al. Follow-up of radiologically totally implanted central venous access ports of upper arm:long-term complications in 127,750 catheter-days. *Am J Roentgenol* 2012;199:447–52.
6. Wang TY, Lee KD, Chen PT, Chen MC, Chen YY, Huang CE, et al. Incidence of risk factors for central venous access port-related infection in chinese cancer patients. *J Formos Med Assoc* 2015;114:1055–60.
7. Zerati AE, Figueredo TR, de Moraes RD, da Cruz AM, da Motta-leal Filho JM, Freire MP, et al. Risk factors for infectious and non infectious complications of totally implantable venous catheters in cancer patients. *J Vasc Surg Venous Lymphat Disord* 2016;4:202–205.
8. Hsu JF, Chang HL, Tsai MJ, Tsai YM, Lee YL, Chen PH, et al. Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli. *World J Surg Oncol* 2015;13:288.
9. Momeni A, Mardani S, Kabiri M, Amir M. Comparison of complications of arteriovenous fistula with permanent catheter in haemodialysis patients: a six-month follow-up. *Adv Biomed Res* 2017;28:106.